Moreover, ∆N‐DGKk expression in mouse brain using adeno‐associated virus Rh10 (AAV Rh10) has no overt side effect in wild‐type mouse while it is able to correct brain lipid profile dysregulations and to achieve long‐term behavioral rescue (over 8 weeks after injection) of Fmr1‐KO mouse, providing a first proof of principle of DGKk gene therapy in a mouse model of FXS. This evidence concerns the gene DGKK and fragile X syndrome.